Biosimilars are simultaneously the most consequential competitive threat facing branded pharmaceutical companies and the most significant cost-containment opportunity available to healthcare systems globally. The $300 billion patent cliff approaching between 2025 and 2030 will transfer revenues at a scale unprecedented in pharmaceutical history.
Humira’s biosimilar story is the most instructive case study. Peak revenues of $21 billion declined to $4.5 billion in 2025 — a 79% decline in three years driven by seven biosimilar entrants in the U.S. market. The Humira blueprint is being studied and applied by every company facing the next wave of biosimilar competition.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Humira Biosimilar Case Study
• Biosimilar Manufacturer Competitive Landscape
• Patent Cliff 2025-2030
• Originator Patent Cliff Management
• U.S. and European Biosimilar Market Dynamics
• Emerging Market Biosimilars
Table of Contents
1. Executive Summary
2. Market Overview
3. Humira Biosimilar Case Study
4. Patent Cliff 2025-2030
5. Originator Patent Cliff Management
6. U.S. and European Biosimilar Market Dynamics
7. Emerging Market Biosimilars
8. Competitive Landscape
9. Regional Market Analysis
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Market Overview and Leading Products 2025
Table 2. Competitive Landscape by Sub-Segment 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Pipeline Assessment 2025
Table 4. M&A and Licensing Activity 2023-2025
Table 5. Regional Market Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Sandoz
Celltrion
Samsung Bioepis
Coherus
Organon
Amneal
Viatris
Fresenius Kabi
